retatrutide phase 2 nejm 2023 obesity trial results GLP-1 Medications for Weight Loss: Semaglutide vs Tirzepatide vs Retat – Revolution Health & Wellness Retatrutide hits 28% weight loss

In its Q4 2025 earnings call, Andrew Dudum, co-founder and CEO, noted that the company's "weight loss offering reached $100 million revenue run rate in less than seven months after launch." This speed outstripped its other offerings, which took "three and sometimes even four years to (inaudible) $100 million in annual revenue." This revenue boost occurred despite the significant blowback Hims & Hers faced when it initially announced plans to advertise and sell compounded versions of FDA-approved GLP-1 medications

10.1016/j.redox.2025.103702 62 LiuT.ZhangL.JooD.SunS

We will ship all of your orders using USPS with a verified tracking number for online tracking and delivery confirmation

Your Lyophilized Peptide Vial: This is your starting point